research Generalized hair loss induced by indinavir plus ritonavir therapy
Indinavir and ritonavir therapy can cause reversible hair loss.
Search
for
Sort by
Research
690-720 / 1000+ results
research FRI0152 METHOTREXATE TREATMENT PATTERNS IN ADVANCED THERAPY–NAïVE PATIENTS WITH RHEUMATOID ARTHRITIS: CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS IN THE CORRONA REGISTRY
Most patients with rheumatoid arthritis continued methotrexate treatment over two years, but those who stopped and restarted experienced more side effects and less improvement.
research RASopathic alopecia: Hair changes associated with vemurafenib therapy
Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.
research Anais do II Congresso Nacional Acadêmico de Dermatologia
Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.
research Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer
Adding celecoxib to chemotherapy improves survival and quality of life for gastric cancer patients with positive COX-2.
research 27604 Response to baricitinib in the treatment of patients with early and late onset alopecia areata in the phase 2 portion of BRAVE-AA1 randomized controlled trial
Baricitinib was effective in treating both early and late onset alopecia areata.
research Combination of All-Trans Retinoic Acid Resumes the Sustained Response of TPO-RA in ITP
Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.
research Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is effective long-term for treating alopecia areata in teens.
research Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
research PEGylated thymosin β4 is a thiol‐site‐specific prodrug treating myocardial infarction in vivo
PEGylated thymosin β4 shows promise for treating heart attacks effectively.
research An Unusual Case of Thalamic Stroke in a Young Adult With Patent Foramen Ovale and Finasteride Use
Stopping finasteride and closing PFO can help prevent strokes in young adults.
research Editorial Comment
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
research 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research Adverse Dermatologic Effects of Cardiovascular Drug Therapy: Part III
Cardiovascular drugs can cause various skin problems, so recognizing these reactions is important.
research Central retinal vein occlusion with secondary cilioretinal artery occlusion following oral minoxidil use: A case report and literature review
Oral Minoxidil can cause serious eye problems, but stopping it can improve vision.
research Evaluating the effect of ursodeoxycholic acid (UDCA) in comparison with dexamethasone and diclofenac in a rat model of rheumatoid arthritis
UDCA reduces inflammation and joint damage in rheumatoid arthritis.
research Simultaneous Quantification of Dutasteride and Silodosin Using a Stability-Indicating RP-HPLC Approach
The method accurately and quickly measures silodosin and dutasteride in mixtures.
research EXPERIENCE WITH ANIFROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH NEUROLOGICAL MANIFESTATIONS
Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.
research The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
research Reporting on Adverse Clinical Events
Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research Ponatinib-induced pityriasis rubra pilaris-like adnexal dysmaturation: A case report
Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
research Does Inhibition of Aldose Reductase Contribute to the Anti-Inflammatory Action of Setipiprant?
Setipiprant may reduce inflammation by blocking an enzyme called aldose reductase.
research Update: baricitinib for alopecia areata
Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
research Study of the interaction between self-assembling peptide and mangiferin and in vitro release of mangiferin from in situ hydrogel
RADA16-I can effectively deliver and release mangiferin, improving its solubility and bioavailability.
research The Advances of Broad-Spectrum and Hot Anti-Coronavirus Drugs
We need safe, affordable drugs to fight coronaviruses effectively.
research Synthesis of avicequinone c and analogs toward the study of 5α-reductase inhibitory activity
2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.